Cargando…
Nasal sprays for treating COVID-19: a scientific note
Clinical management of COVID-19 has been a daunting task. Due to the lack of specific treatment, vaccines have been regarded as the first line of defence. Innate responses and cell-mediated systemic immunity, including serum antibodies, have been the primary focus of practically all studies of the i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969373/ https://www.ncbi.nlm.nih.gov/pubmed/36848033 http://dx.doi.org/10.1007/s43440-023-00463-7 |
_version_ | 1784897706049667072 |
---|---|
author | Chavda, Vivek P. Baviskar, Kajal P. Vaghela, Dixa A. Raut, Shilpa S. Bedse, Anjali P. |
author_facet | Chavda, Vivek P. Baviskar, Kajal P. Vaghela, Dixa A. Raut, Shilpa S. Bedse, Anjali P. |
author_sort | Chavda, Vivek P. |
collection | PubMed |
description | Clinical management of COVID-19 has been a daunting task. Due to the lack of specific treatment, vaccines have been regarded as the first line of defence. Innate responses and cell-mediated systemic immunity, including serum antibodies, have been the primary focus of practically all studies of the immune response to COVID-19. However, owing to the difficulties encountered by the conventional route, alternative routes for prophylaxis and therapy became the need of the hour. The first site invaded by SARS-CoV-2 is the upper respiratory tract. Nasal vaccines are already in different stages of development. Apart from prophylactic purposes, mucosal immunity can be exploited for therapeutic purposes too. The nasal route for drug delivery offers many advantages over the conventional route. Besides offering a needle-free delivery, they can be self-administered. They present less logistical burden as there is no need for refrigeration. The present article focuses on various aspects of nasal spray for eliminating COVID-19. |
format | Online Article Text |
id | pubmed-9969373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-99693732023-02-28 Nasal sprays for treating COVID-19: a scientific note Chavda, Vivek P. Baviskar, Kajal P. Vaghela, Dixa A. Raut, Shilpa S. Bedse, Anjali P. Pharmacol Rep Review Clinical management of COVID-19 has been a daunting task. Due to the lack of specific treatment, vaccines have been regarded as the first line of defence. Innate responses and cell-mediated systemic immunity, including serum antibodies, have been the primary focus of practically all studies of the immune response to COVID-19. However, owing to the difficulties encountered by the conventional route, alternative routes for prophylaxis and therapy became the need of the hour. The first site invaded by SARS-CoV-2 is the upper respiratory tract. Nasal vaccines are already in different stages of development. Apart from prophylactic purposes, mucosal immunity can be exploited for therapeutic purposes too. The nasal route for drug delivery offers many advantages over the conventional route. Besides offering a needle-free delivery, they can be self-administered. They present less logistical burden as there is no need for refrigeration. The present article focuses on various aspects of nasal spray for eliminating COVID-19. Springer International Publishing 2023-02-27 2023 /pmc/articles/PMC9969373/ /pubmed/36848033 http://dx.doi.org/10.1007/s43440-023-00463-7 Text en © The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Chavda, Vivek P. Baviskar, Kajal P. Vaghela, Dixa A. Raut, Shilpa S. Bedse, Anjali P. Nasal sprays for treating COVID-19: a scientific note |
title | Nasal sprays for treating COVID-19: a scientific note |
title_full | Nasal sprays for treating COVID-19: a scientific note |
title_fullStr | Nasal sprays for treating COVID-19: a scientific note |
title_full_unstemmed | Nasal sprays for treating COVID-19: a scientific note |
title_short | Nasal sprays for treating COVID-19: a scientific note |
title_sort | nasal sprays for treating covid-19: a scientific note |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969373/ https://www.ncbi.nlm.nih.gov/pubmed/36848033 http://dx.doi.org/10.1007/s43440-023-00463-7 |
work_keys_str_mv | AT chavdavivekp nasalspraysfortreatingcovid19ascientificnote AT baviskarkajalp nasalspraysfortreatingcovid19ascientificnote AT vagheladixaa nasalspraysfortreatingcovid19ascientificnote AT rautshilpas nasalspraysfortreatingcovid19ascientificnote AT bedseanjalip nasalspraysfortreatingcovid19ascientificnote |